

Reporting of transactions in shares and associated securities of Chr. Hansen Holding A/S by senior employees

Pursuant to section 28a of the Securities Trading Act, Chr. Hansen Holding A/S is required to disclose information on transactions with the shares and associated securities of Chr. Hansen Holding A/S by senior employees and their associated persons or companies.

Chr. Hansen Holding A/S has received information on below transactions:

Name of the reporting person	Cornelis (Cees) de Jong
Reason for the reporting	Chief Executive Officer
Name of the issuer	Chr. Hansen Holding A/S
Securities code	DK 0060227585
Nature of the transaction	Purchase of shares in Chr. Hansen Holding A/S
Type of security	Shares
Trading date	20 November 2014
Trading market	Nasdaq Copenhagen
Number of securities	5,277
Market value on the trading date	DKK 1,321,034.40

Tel. +45 45 74 74 74

CVR-no: 28318677

www.chr-hansen.com

Name of the reporting person	Knud Vindfeldt
Reason for the reporting	Executive Vice President
Name of the issuer	Chr. Hansen Holding A/S
Securities code	DK 0060227585
Nature of the transaction	Exercise of stock options in Chr. Hansen Holding A/S
Type of security	Stock options
Trading date	20 November 2014
Trading market	Nasdaq Copenhagen
Number of securities	24,342
Market value on the trading date	DKK 2,308,838.70

Name of the reporting person	Knud Vindfeldt
Reason for the reporting	Executive Vice President
Name of the issuer	Chr. Hansen Holding A/S
Securities code	DK 0060227585
Nature of the transaction	Sale of shares in Chr. Hansen Holding A/S
Type of security	Shares
Trading date	20 November 2014
Trading market	Nasdaq Copenhagen
Number of securities	24,342
Market value on the trading date	DKK 6,083,643.20

For further information, please contact:

Anders Mohr Christensen, Senior Director, Investor Relations

Tel: +45 4574 7618

Eva Veileborg Hald, Director, Corporate Communications

Tel: +45 4574 7474

About Chr. Hansen

Chr. Hansen is a global bioscience company that develops natural ingredient solutions for the food, nutritional, pharmaceutical and agricultural industries. The products include cultures, enzymes, probiotics and natural colors, and all solutions are based on strong research and development competencies coupled with significant technology investments. Revenue in the 2013/14 financial year was EUR 756 million. The company holds a leading market position in all its divisions: Cultures & Enzymes, Health & Nutrition and Natural Colors. It has more than 2,500 dedicated employees in 30 countries and main production facilities in Denmark, France, USA and Germany. Chr. Hansen was founded in 1874 and is listed on Nasdaq Copenhagen. For further information, please visit www.chr-hansen.com.

Reporting of transactions in shares and associated securities of Chr. Hansen Holding A/S by senior employees

Page 3/3